|Ms. Adelene Q. Perkins||Chairman & CEO||1.15M||N/A||1960|
|Dr. Stephane Peluso Ph.D.||Chief Scientific Officer||577.63k||N/A||1970|
|Dr. Robert Ilaria Jr., M.D.||Chief Medical Officer||643.54k||N/A||1961|
|Dr. Lawrence E. Bloch J.D., M.D.||Pres & Treasurer||N/A||N/A||1966|
|Ms. Melissa Hackel||VP of Fin.||N/A||N/A||N/A|
|Dr. Jeffery L. Kutok M.D., Ph.D.||Chairman of Scientific Advisory Board||N/A||N/A||1967|
|Mr. Seth A. Tasker J.D.||Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec.||N/A||N/A||1979|
|Ms. Rossitza Alargova Ph.D.||Head of Pharmaceutical Devel.||N/A||N/A||N/A|
|Jayne Kauffman||Sr. Exec. Coordinator||N/A||N/A||N/A|
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 July 2022 is 5. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 3; Compensation: 7.